Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|May 29, 2014

BioPlan Associates Releases 11th Annual Global Biomanufacturing Study

The 11th Annual Global Biomanufacturing Study includes a global analysis of 238 biomanufacturers and 178 suppliers in 31 countries.

BioPlan Associates has released the 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production. This report includes a global analysis of 238 biomanufacturers and 178 suppliers in 31 countries. The 514-page study contains 11 years of biopharma trends and opportunities, including analysis of specific issues affecting the industry. The report covers the events shaping the past year, and evaluates what will shape the industry over the next five years. The study focuses on 12 areas, including industry growth, downstream processing, single use systems, outsourcing, capacity, and quality management.

The data on global capacity reveals how the impact of biosimilars, outsourcing, regulatory, as well as downstream processing and single-use devices, are creating growth potential in both capacity and in the number of facilities coming on-line. Capacity utilization remains overall constant across mammalian and microbial systems, according to this year's respondents. This will affect, overall industry growth, opportunities for suppliers to the industry, demand for skilled staff and better technology, and regulatory demands on the industry.

In addition, the report features analysis on how trends such as mAbs, biosimilars, outsourcing, and disposables are creating opportunities and challenges to the entire industry. The study also compares over time how Western Europe, the US, and other global biomanufacturers differ in demands for new technologies.

Source: BioPlan Associates


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.